Hydromorphone - Daiichi Sankyo

Drug Profile

Hydromorphone - Daiichi Sankyo

Alternative Names: DS-7113; DS-7113b; Hydromorphone HCl - Daiichi Sankyo; Hydromorphone hydrochloride - Daiichi Sankyo

Latest Information Update: 03 Feb 2017

Price : $50

At a glance

  • Originator Daiichi Sankyo Company
  • Class Morphine derivatives; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Preregistration Cancer pain

Most Recent Events

  • 02 Feb 2017 Daiichi Sankyo announces intention to seek approval or launch hydromorphone IV and SC formulations in 2018 (Daiichi Sankyo pipeline, February 2017)
  • 30 Apr 2016 Daiichi Sankyo completes a phase II/III trial in Cancer pain in Japan (JapicCTI-142735)
  • 30 Apr 2016 Daiichi Sankyo completes a phase II/III trial in Cancer pain in Japan (JapicCTI-142736)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top